A case report of advanced male breast cancer with an objective response to tamoxifen treatment

Breast Cancer

Volumn 7, Issue 3, 2000, Pages 256-260

  Kanoh, Takayuki ^a   Lino, Yuichi ^b   Horiguchi, Jun ^a   Takei, Hiroyuki ^a   Maemura, Michio ^a   Yokoe, Takao ^b   Morishita, Yasuo ^a  

^a GUNMA UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

Estrogen receptor; Hormonal therapy; Male breast cancer; Tamoxifen

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TAMOXIFEN;

AGED; ARTICLE; BIOPSY; BRAIN TUMOR; BREAST TUMOR; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FATALITY; HUMAN; LUNG TUMOR; MALE; METASTASIS; PAGET NIPPLE DISEASE; PATHOLOGY; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BIOPSY; BRAIN NEOPLASMS; BREAST NEOPLASMS, MALE; CARCINOMA, DUCTAL, BREAST; FATAL OUTCOME; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; QUALITY OF LIFE; TAMOXIFEN; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0034564555     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967470     Document Type: Review

References (24)

1. Crichlow RW: Carcinoma of the male breast. Surg Gynecol Obstet 134:1011-1019, 1972.
2. Ciatto S, Iossa A, Bonardi R: Male breast carcinoma: Review of a multicenter series of 150cases. Tumori 76:555-558, 1990.
3. Bogen PI, Wong GY, Vlamis V: Current management of male breast cancer. Ann Surg 2 15:451-457, 1992.
4. Guinee VF, Olsson H, Moller T, et al: The prognosis of breast cancer in males. Cancer 71:154-161, 1993.
5. Moseley HS, Fletcher WS, Leung BS, et al: Predictive criteria for the selection of breast cancer patients for adrenalectomy. Am J Surg 128:143-151, 1974.
6. Everson RB, Lippmann ME, Thonpson EB, et al: Clinical correlations of steroid receptors and male breast cancer. Cancer Res 40:991-997, 1980. (Pubitemid 10135797)
7. Gupta N, Cohen JL, Rosenbaum C, et al: Estrogen receptors in male cancer. Cancer 46:1781-1784, 1980.
8. Friedman MA, Hoffman PG, Dandolos EM, et al: Estrogen receptors in male breast cancer:clinical and pathologic correlations. Cancer 47:134-137, 1981. (Pubitemid 11167371)
9. Cantwell BMJ, Tong D, Minton M, et al: Tamoxifen and male breast cancer. Lancet 2:582-583, 1978. (Pubitemid 9013092)
10. Morgan DAL, Hong A: Carcinoma of the male breast and oestrogen metabolism. Br Med 12:206, 1978.
11. Abele R, Alberto P, Megevand R: Carcinoma of the male breast and oestrogen metabolism. Br Med J 1:1697-1698, 1978.
12. Aisner J, Ross DD, Wiernik PH: Tamoxifen in advanced male breast cancer. Arch Intern Med 139:480-481, 1979. (Pubitemid 10150833)
13. Patterson JS, Battersby LA, Bach BK: Use of tamoxien in advanced male breast cancer. Cancer Treat Rep 64:801-804, 1980. (Pubitemid 11199497)
14. Rebeiro GG, Swindell R: Adjuvant tamoxifen for male breast cancer (MBC). Br J Cancer 65:252-254, 1992.
15. Becher R, Hoflken K, Pape H, et al: Tamoxifen treatment before orchiectomy in advanced breast cancer in men. New Engl J Med 305:169, 1981.
16. Tirelli U, Tumolo S, Talamini R, et al: Tamoxifen before and orchiectomy in advanced male breast cancer. Cancer Treast Rep 66:1882-1883, 1982. (Pubitemid 12005318)
17. Ribeiro GG: Tamoxifen in treatment of male breast carcinoma. Clin Radiol 34:625-628, 1983. (Pubitemid 14244130)
18. Anelli MTF, Anelli A, Tran KN, et al: Tamoxifen administration is associated with a high rate of treatment-limiting symptoms in male breast cancer patients. Cancer 74:74-77, 1994. (Pubitemid 24187612)
19. Kraybill WG, Kaufman R, Kinne D: Treatment of advanced male breast cancer. Cancer 47:2185-2189, 1981. (Pubitemid 11098587)
20. Pannuti F, Martoni A, Busutti L, et al: High-dose medroxy-progesterone acetate in advanced male breast cancer. Cancer Treat Rep 66:1763-1765, 1982. (Pubitemid 12000634)
21. Bezwoda WR, Hesdorffer C, Dansey R, et al: Breast cancer in men. Clinical features, hormone receptor status, and response to therapy. Cancer 60:1337-1340, 1987. (Pubitemid 17152916)
22. Doberauer C, Niederle N, Schmidt CG, et al: Advanced male breast cancer treatment with the LHRH analogue buserelin alone or in combination with the antiandrogene flutamide. Cancer 72:474-478, 1988.
23. Lopez M, Natali M, Lauro LD, et al: Combined treatment with buserelin and cyproterone acetate in matastatic male breast cancer. Cancer 72:502-505, 1993. (Pubitemid 23193458)
24. Sasano H, Kimura M, Shizawa S, et al: Aromatase and steroid receptors in gynecomastia and male breast carcinoma:an immunohistochemical study. J Clin Endocrino Metab 81:3063-3067, 1996. (Pubitemid 26323909)